CNS Drug Development: Lessons Learned Part 2. Symptoms, Not Syndromes as Targets Consistent with the NIMH Research Domain Approach PRESKORN, SHELDON H. PRESKORN, SHELDON H. Less Journal of Psychiatric Practice®. 21(1):60-66, January 2015. Abstract Abstract Favorites PDF Get Content & Permissions Buy
CNS Drug Development: Lessons from the Development of Ondansetron, Aprepitant, Ramelteon, Varenicline, Lorcaserin, and Suvorexant. Part I PRESKORN, SHELDON H. PRESKORN, SHELDON H. Less Journal of Psychiatric Practice®. 20(6):460-465, November 2014. Abstract Abstract Favorites PDF Get Content & Permissions Buy SDC
